As the world’s largest single pharmaceutical market, the US should – at least at first glance – provide a simplified pathway for companies looking for a stateside translation of their successes in Europe’s patchwork quilt of countries. Unfortunately, that’s anything but the case.
In this white paper, Howard Miller, CEO of Two Labs, discusses how companies looking to replicate a drug’s EU market success in the US will face significant hurdles – unless they are fully aware of the ever-changing national and state requirements and regulations.